Podcast appearances and mentions of Jonathan Palmer

“We exist to solve prior authorization so patients can get the care they deserve,” says Dr. Jeremy Friese, founder and CEO of Humata Health. Friese joins Bloomberg Intelligence health-care analyst Jonathan Palmer to discuss how Humata’s AI-driven technology is transforming one of health care’s most notorious administrative headaches. They cover how Humata connects deeply into medical records, helps both providers and payers streamline approvals and is expanding into specialty pharmacy. Friese also shares his journey from Mayo Clinic radiologist to serial entrepreneur — and why he believes solving back-office burdens can unlock better patient care.See omnystudio.com/listener for privacy information.

“Health care is finally ready to operate at information speed,” says Jonathan Bush, co-founder and CEO of Zus Health. Bush joins Bloomberg Intelligence analyst Jonathan Palmer to explain why he believes health care is poised for a digital transformation. He unpacks how Zus uses AI and FHIR-native tools to pull patient data from fragmented sources, clean it and serve it back to providers in actionable form. From uncovering the “fire in the trash” to helping doctors identify high-risk patients before costs spike, Bush shares what it means to be a modern health-tech platform and why he came out of retirement to build it. They also discuss the early customers driving growth, lessons from Athenahealth and why gross margin, not buzz, is the new benchmark for digital health.See omnystudio.com/listener for privacy information.

Newly appointed Ulster County historian Eddie Moran discusses the role of a municipal historian and emphasizes the importance of presenting a complete and accurate history that includes all groups, with one such focus on the indigenous Lenape people. Moran, a SUNY New Paltz graduate and descendant of the region's Huguenot and Dutch colonists, shares his experiences working with various local organizations to expand the historical narrative. The episode also features a tour of the Ulster County Hall of Records led by archivist Jonathan Palmer, exploring the extensive archival collections and discussing the preservation and digitization efforts.00:00 Introduction and Context00:27 Meet Eddie Moran: Ulster County's New Historian01:38 Eddie's Journey and Passion for History06:55 The Role and Responsibilities of a County Historian10:54 Challenges and Goals in Historical Narratives16:50 Exploring the Ulster County Hall of Records19:34 Preserving History: Techniques and Challenges27:38 Significant Historical Documents and Their Stories38:55 Conclusion and Credits---Audio recording by Izzy SchuylerBehind-the-scenes video by Ruby Zuckerman

On this episode of the Astonishing Healthcare podcast, Bloomberg Intelligence's Jonathan Palmer (Sr. Equity Analyst & Team Lead, Healthcare) joins us in the studio for a discussion about the work his team does and the evolving landscape of health tech. Palmer notes interest in Hinge Health's potential IPO and how the market's receptivity to tech-enabled healthcare companies has improved recently. While these companies face pressure to demonstrate profitability amid evolving market dynamics, there's optimism about innovation on several fronts. He also explains the impact of health policy uncertainty and questions about what the FDA, FTC, DOJ, and CMS will do on investors' ability to place bets: ambiguity causes market hesitation, and investors gravitate toward safe havens.The discussion also covers areas of focus for 2025, including:Palmer's favorite Vanguards of Healthcare podcast episodes and why he enjoys speaking with private company CEOs and venture capital leadersBiopharma Innovation, including GLP-1s, oncology readoutsMedTech Advancements like surgical robotics, cardioablation, and evolving insulin delivery systemsCapital Spending Concerns as US providers and China's healthcare sector are under scrutinyHealthcare Services: online pharmacy growth and Medicare Advantage trendsReference Materials Courtesy of Bloomberg IntelligenceNorth America Managed-Care Policy OutlookN.A. Health-Care Tech, Distribution: 2025 OutlookRelated ContentVanguards of Health Care: How Capital Rx is Fixing America's Broken Drug PricingAH057 - How First-Movers are Taking Control of their Health Plans in 2025, with Jeff HoganAH047 - What Project 2025, RFK Jr., and Dr. Oz Could Mean for the Business of Healthcare Under TrumpAH046 - What's Hot In and Around the Pharmacy Supply Chain, with RSM's Tom EveganFor more information about Capital Rx and this episode, please visit Capital Rx Insights.

“We decided to come to the table with a health-plan model that enables what we like to call radical affordability,” said Ashok Subramanian, CEO and co-founder of Centivo, in this episode of the Vanguards of Health Care podcast. Subramanian joins Bloomberg Intelligence analyst Jonathan Palmer to discuss how Centivo’s approach to self-funded employer plans focuses on reducing costs without sacrificing quality. By leveraging direct-provider partnerships and emphasizing primary care, the company aims to keep 75% of members’ out-of-pocket costs below $200 per year. The conversation covers how Centivo differentiates itself from traditional insurers, its expansion into new markets, and how it helps employers navigate high-cost treatments like GLP-1 drugs while maintaining sustainable benefits for workers. See omnystudio.com/listener for privacy information.

"The mission of Capital Rx is to give our country the infrastructure we need for the healthcare we deserve." AJ Loiacono, CEO and co-founder of Capital Rx, shares with Bloomberg Intelligence analyst Jonathan Palmer how his company is reshaping the pharmacy benefit management (PBM) industry by eliminating hidden costs and conflicts of interest. He explains how traditional PBMs profit from inflated drug prices, creating a system where the most expensive drugs are preferred over more affordable alternatives. Capital Rx aims to disrupt this model by using technology to reduce administrative costs and promote transparency. The discussion also covers regulatory reform and how AI-driven claims processing, with a unified approach to medical and pharmacy benefits, could unlock massive cost savings.See omnystudio.com/listener for privacy information.

"The conversation is the treatment in behavioral health, but clinicians spend too much time documenting instead of caring,” says Alon Joffe, CEO and cofounder of Eleos Health, in this episode of the Vanguards of Health Care podcast. Joffe joins Bloomberg Intelligence analyst Jonathan Palmer to discuss how Eleos is revolutionizing behavioral health care with AI-driven solutions that reduce administrative burdens by 80% while enhancing clinical outcomes. He shares how Eleos leverages multimodal AI to automate documentation and improve decision-making, enabling clinicians to provide better care. The conversation explores Eleos’ expansion into psychiatry, substance-use treatment and long-term care, as well as its vision to become the AI-native operating system for compassionate care.See omnystudio.com/listener for privacy information.

“There’s no digital feedback loop in health care, you have it in Tesla, in Netflix, in Amazon — but not in the industry that impacts every life,” Terry Myerson, CEO of Truveta, explains to Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Myerson joins BI analyst Jonathan Palmer to discuss Truveta’s mission to aggregate and analyze health data across 30 major US health systems, covering one-third of Americans. He details the company’s work in regulatory-grade safety and efficacy research, the launch of the Truveta Genome Project with partners like Regeneron and Illumina, and the power of AI-driven insights to accelerate medical discovery. The conversation explores Truveta’s efforts to address data fragmentation, privacy, and interoperability challenges that must be solved to revolutionize patient care and life sciences.See omnystudio.com/listener for privacy information.

“We sit at the intersection of those large-scale incumbents and entrepreneurs, to help bridge the gap,” Josh Flum, managing partner at LRVHealth, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Flum joins BI analyst Jonathan Palmer to discuss how LRV’s purpose-built model looks to identify and capitalize on durable long-term trends emerging in health care. With only strategic investors as limited partners, LRV believes it has a differentiated perspective on where the market is headed. The conversation delves into the evolution of pharmacy services and why it’s important to build high-performing teams. The exchange wraps up with the state of the IPO market and key takeaways from the JPMorgan Healthcare conference.See omnystudio.com/listener for privacy information.

“The average benefit value for supplemental benefits was about $155 per member. Five years later, it was over $1,500 per member,” Robby Knight, CEO and cofounder of Soda Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Knight joins BI analyst Jonathan Palmer for a wide-ranging discussion on the rapid evolution of the supplemental-benefits market and the challenges Soda faced in building in a new platform that creates incentives for members, retail partners and plan sponsors. The conversation touches on why Medicare Advantage plans were in an arms race to offer unsustainable benefits, why the correction is an opportunity for the company and how the future will bring optimized benefits at the member level.See omnystudio.com/listener for privacy information.

“Our mission is to make cancer less deadly through widely accessible next-generation early-detection blood tests.” Susan Tousi, CEO of Delfi Diagnostics, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Tousi joins BI analyst Jonathan Palmer to discuss the company's fragment-based liquid biopsy technology and the immense opportunity to save lives through early cancer detection. Starting with lung cancer via its FirstLook test, Delfi expects to expand more broadly into other cancer types and applications like monitoring with a focus on access and affordability. The conversation touches on the company's core values and the large opportunity set afforded by recent funding rounds.See omnystudio.com/listener for privacy information.

"A number of art schools in the early 60s said: “Clearly, it is the relationship of the painter to the medium that is the essence of painting - the painter must be emotionally present, and this is what we should instill in our students.” So they started to take away traditional training in art schools of representational drawing, of color theory, of figurative drawing, and what they ended up with was a generation of artists who were passionately throwing paint at canvases but unable to make art. The relationship between the fundamentals and intuition is very complicated. Nobody seemed to make the point that the great abstract expressionists  were all trained for decades in traditional art schools. That's what they came out of, and we see this in our analytic colleagues. Many of them are writing wonderfully at the moment, but they were trained as Kleinians or trained as ego psychologists, and they have that in their bone marrow. The kind of representational work with Apple [painting of his dog] that I am talking about when I say: I draw and I draw and I draw until I can put that aside, in analytic work I go to something basic in my training. For me it happens to be something that's close to Paul Gray, it's not where I'm going to stop, but I can use Paul Gray because that's what I was trained in - I will look for transference, I'll look for defense, I'll look for resistance and I'll go back and look for the derivatives of certain affects that are enacted in the relationship. I go over it and over it until I can relinquish it like I did with the painting of Apple, and then the intuitive comes in, but the intuitive is the reward at the end of decades of hard work."   Episode Description: We begin with Jon's mother's encouragement to paint by finding the bird's vitality through "becoming the bird." This leads us to consider the relationship between intuitive seeing and the "images which I might desire to produce." We discuss his notion of the aesthetic matrix which applies both to the analytic encounter as it does to the painter's relationship to his creative process. Jon shares with us his conviction that basic technique, whether artistic or analytic, must first become part of one's inner make-up before intuition can enlighten an obscure moment. He walks us through his creative process in the face of a blank canvas on the wall in front of him. He discusses the different uses of watercolor and oil paint and how their unique properties parallel his spontaneous engagement at various periods of an analysis. He presents a clinical encounter and how he was able to unpack a countertransference impasse through working on a painting. He closes with sharing an experience he had in his native South Africa which leads him to feel that "it's a blessing to be able to work in America."   Linked Paper and Websites: The Aesthetic Matrix: A Conversation Between a Painter and a Psychoanalyst  

“When I looked at the industry, I saw a real opportunity set to build a best-in-class sector-focused fund,” Lynne Chou O'Keefe, founder and managing partner of Define Ventures, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. O'Keefe joins BI analyst Jonathan Palmer for a deep discussion into Define's unique approach to health-care investing, emphasizing the importance of both health-care and tech expertise. The two discuss the major trends shaping health care, including technology, consumerization and the evolution of the value chain. The podcast concludes with insights into the state of the market, including valuations, IPOs and potential consolidation.See omnystudio.com/listener for privacy information.

On this week's My Week In Cars podcast our hosts Matt Prior and Steve Cropley are joined live at the Royal Automobile Club in London by Jonathan Palmer, CEO of MotoSport Vision. Hosted on Acast. See acast.com/privacy for more information.

“Our liquid biopsy test alone, we estimate one in four cancer patients in the US are getting it,” Helmy Eltoukhy, cofounder and co-CEO of Guardant Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Eltoukhy joins BI analyst Jonathan Palmer to discuss the underpinnings of the liquid biopsy revolution and how Guardant has stuck to its technology road map since its founding in 2012, launching products in each of the three major market categories. The conversations also covers the company's recent approval of its Shield colorectal screening test as well as many of the scientific and commercial challenges to standing up the business.See omnystudio.com/listener for privacy information.

Listen in as Jonathan Palmer, CEO of Autometrix and member of the ATA Board of Directors, interviews Ethan Halpern, President of American Awning & Blind Co., Daniel Cuppels, Operations Manager at Blithe Defense Industrial Covers, and Alberto Ramirez, CEO of Just 4U Custom Canvas, Inc. They will discuss what makes their textile businesses unique and different on the West Coast. They will also discuss how ATA has helped them become more knowledgeable in the industry with online resources like the member directory and holding Expo each year so they can meet and network with individuals and companies.

“Tempus is focused on the idea of bringing technology, and in particular artificial intelligence, to diagnostics by essentially combining a molecular result and then connecting that to clinical data for that patient.” Eric Lefkofsky, Founder and CEO of Tempus AI, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Lefkofsky joins BI analyst Jonathan Palmer for a discussion on how Tempus built a multipurpose platform that generates unique insights not only for treating patients but also in drug discovery and speeding recruitment for clinical trials. The two cover how oncology is just the first beachhead, why it's still early days for the company's data business and the future of using algorithms in treatment.See omnystudio.com/listener for privacy information.

 "If all goes well, Heartbeat Health will be a household name for the first referral from primary care for cardiology. It'll be easier than everyone else out there and less expensive than other referrals." Dr. Jeff Wessler, CEO and Founder of Heartbeat Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Dr. Wessler joins BI analyst Jonathan Palmer to discuss the genesis of Heartbeat's decentralized cardiology practice, how the company iterated from a brick and mortar clinic to a virtual platform to speed access, and why keeping patient care at the center has improved outcomes.  See omnystudio.com/listener for privacy information.

 "We analyze vocal biomarkers in near real time and correlate that to a clinical diagnosis and create an algorithm that then can independently identify a range of different diseases in the human voice during conversation," Henry O'Connell, CEO and Co-founder of Canary Speech, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. O'Connell joins BI analyst Jonathan Palmer to discuss the company's origins, its unique approach to vocal analysis using over 2,500 speech features and its commitment to clinical validation through partnerships with leading healthcare institutions. The conversation touches on Canary's foundational team, extensive patent portfolio and platform approach that enables the development of models for a wide range of diseases. See omnystudio.com/listener for privacy information.

“We're staking the company on personalization: If you can make the health-care experience more personal to the individual, they'll be more likely to engage around their health care and take the proper actions to get better outcomes,” Chris Michalak, CEO of Personify Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Michalak joins BI analyst Jonathan Palmer to discuss the merger of Virgin Pulse and HealthComp, the company's AI-driven personalization engine and the value proposition for employers. The conversation also covers Personify's approach to consolidation in health care, the role of navigation and the impact of GLP-1 drugs on the market.See omnystudio.com/listener for privacy information.

“We're here to lower the cost of prescription drugs for every American,” Mark Thierer, CEO of Waltz Health explains to Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Thierer joins BI senior health care analyst Jonathan Palmer to discuss Waltz's Marketplace Search solutions for pharmacies and payers and why the upcoming launch of its Intelligent Specialty Engine is a game changer. He also shares his insights into the latest trends affecting the PBM industry.See omnystudio.com/listener for privacy information.

“We are driving the market to exome and genome testing with a goal of making multigene panels be a thing of the past” Katherine Stueland, CEO of GeneDx, tells Bloomberg Intelligence's analyst Jonathan Palmer on this episode of the Vanguards of Health Care podcast. They discuss GeneDx's 80% market share in exome sequencing, the evolution of the genetic testing market and why the company's core mission is delivering clinically-actionable results in rare diseases.  See omnystudio.com/listener for privacy information.

Hair testing ~ How to really get to know your hair Dr Jonathan Palmer has a PHD from Imperial College and works in Biotechnology. He has worked for cancer research and blood testing, and has now founded Hair Knowhow.Dr Palmer describes himself as an experimentalist, who has been passionate about science since he got his first telescope at 7 years old.He uses tests designed for product development, producing results for people who want to know about their hair health. These hair tests produce impartial, data led diagnoses, which Jonathan describes as a branch of personal medicine.Hair knowhow can test the hair in depth biochemically, inside & out. They can measure protein loss, porosity, lustre and the extent of physical or chemical damage. Their aim is to help people be able to make choices on products & practices that can better look after their hair.They can work with trichologists to enable them to provide a fully comprehensive hair analysis.Connect With Dr Palmer:InstagramWebsite Hair & Scalp Salon Specialist course Support the showConnect with Hair therapy: Facebook Instagram Twitter Clubhouse- @Hair.Therapy Donate towards the podcast Start your own podcastHair & Scalp Salon Specialist Course ~ Book now to become an expert!

When Wegovy was approved in 2021, patients began inquiring about whether Ro could build a product that would give them the “Ro experience” in weight loss: The company went to work at the end of 2021, spent all of 2022 building it, launched in 2023 and is now scaling up, CEO and co-founder Zachariah Reitano explains to Bloomberg Intelligence. In this episode of the Vanguards of Health Care podcast, Reitano sat down with BI analyst Jonathan Palmer to discuss how the Ro platform is uniquely positioned to scale in chronic care, the drivers of unprecedented demand for GLP-1 drugs, how taking friction out of the patient experience led to early success and why he's trying to recreate his physician father with technology.See omnystudio.com/listener for privacy information.

“People who engage with an Included clinician experienced an average of two additional healthy days per month,” Owen Tripp, CEO of Included Health, explains to Bloomberg Intelligence. Tripp joins BI analyst Jonathan Palmer for this episode of the Vanguards of Health Care podcast for a wide-ranging discussion on why “healthy days” are Included's North Star, the evolution of navigation and why over 30% of the Fortune 500 has contracted with the company. The conversation also covers Included's progress in leveraging its care-delivery franchise, work around identifying quality and how member-centric product design improves outcomes while creating value.See omnystudio.com/listener for privacy information.

“We started this company looking at the current genomics field and evaluating the gap we're trying to fill,” Molly He, CEO and co-founder of Element Biosciences, explains to Bloomberg Intelligence. Dr. He joins BI analyst Jonathan Palmer on this Vanguards of Health Care podcast episode to discuss the intricacies of building a new gene-sequencing instrument from scratch, the challenges of getting customers to adopt technology from new entrants and why the extension of the AVITI system beyond DNA into protein and cellular analysis is so important.See omnystudio.com/listener for privacy information.

Episode 73 of the Autocar podcast My Week In Cars finds our resident car hacks Steve Cropley and Matt Prior talking about a good experience with a new fast Ford, the Puma ST, as well as riffing on a classic Rolls-Royce Silver Cloud, commending Jonathan Palmer and Ginetta's new race academy, hoping the Detroit motor show will be back as it should be, and talking much more beside, including your correspondence. Hosted on Acast. See acast.com/privacy for more information.

"This decade will be defined by the affordability crisis and our vision as a company is to solve the affordability crisis in US healthcare," apree health CEO Donald Trigg explains to Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Trigg joins BI senior health care analyst Jonathan Palmer for a deep dive into apree's advanced primary care and digital engagement capabilities, how the combination of Vera Whole Health and Castlight positions the company to bring a differentiated solution set to help employers as well as health plans improve outcomes while lowering costs, and its progress in proving out its thesis across distinct market models.   See omnystudio.com/listener for privacy information.

“It was pretty clear as we looked at pharmacy-cost trends that where we were and where we were trying to go was just unsustainable,” Paul Markovich, CEO of Blue Shield of California explains to Bloomberg Intelligence. Markovich joins BI analyst Jonathan Palmer on this Vanguards of Health Care podcast episode to discuss the details of the company's new prescription model, why it's walking away from traditional pharmacy-benefit managers arrangements and how the insurer is going to generate $500 million in savings on over $4 billion in annual drug spending. Blue Shield's work-around digital innovation, value-based care and the potential of GLP-1 drugs are also highlighted.See omnystudio.com/listener for privacy information.

"We're the only ones in navigation that engage directly with all providers to use health signals from both members and providers to create next best steps," Quantum Health's CEO Zane Burke explains to Bloomberg Intelligence. In this episode of the Vanguards of Health Care podcast, Burke joins BI analyst Jonathan Palmer to discuss the burgeoning need for health-care navigation and advocacy in a deep dive on Quantum's capabilities and how they improve clinical outcomes while generating a positive return on investment for clients. He also touches on a recent benefits survey that showed 60% of consultants recommend navigation for their clients and how Quantum's member engagement figures were the catalyst for joining the company. See omnystudio.com/listener for privacy information.

“We've come in with an offering that's broader and deeper than a lot of data aggregators, but on top of that we've built really simple software that allows people in a no-code sort of way to just ask questions that they can get answers to instantly, and that's why we're winning,” Komodo Health cofounder and CEO Arif Nathoo explains. In this episode of the Vanguards of Health Care podcast, Nathoo sits down with Bloomberg Intelligence analyst Jonathan Palmer for a detailed discussion on the origins of Komodo's data and analytics platform, the nuances that differentiate it for enterprise customers and the power of its longitudinal Healthcare Map database.See omnystudio.com/listener for privacy information.

The 20-30% where a provider is actually making a clinical decision is what makes or breaks the outcome but the problem is that 100% of that work is manually driven, Memora Health cofounder and CEO Manav Sevak explains. In this episode of the Vanguards of Health Care podcast, Sevak joins BI analyst Jonathan Palmer for a deep dive into how Memora helps optimize care delivery and the patient experience against a backdrop where providers and payors are searching for alignment in complex businesses. See omnystudio.com/listener for privacy information.

Women and families are underserved in the health-care system, with almost 40% of US counties lacking an obstetrics-gynecologist, Maven Clinic founder and CEO Kate Ryder explains to Bloomberg Intelligence analyst Jonathan Palmer in this episode of the Vanguards of Health Care podcast. Ryder speaks in depth about unmet needs as the driver behind building the world's largest virtual clinic for women and family health with a platform that covers 15 million lives spanning fertility, pregnancy, pediatrics and menopause. She highlights the challenges facing employers after the Dobbs decision, how international growth is exploding and why learning to be resilient is key. See omnystudio.com/listener for privacy information.

Color Health is delivering care programs in the public and private sectors that vertically integrate disparate workflows to drive outcomes for all stakeholders, cofounder and CEO Othman Laraki tells Bloomberg Intelligence. In this episode of the Vanguards of Health Care podcast, Laraki sits down with BI analyst Jonathan Palmer for a discussion on the company's pivot to health delivery, the challenges facing self-insured employers, its partnership with the American Cancer Society and why fee-for-service shouldn't be a dirty word. See omnystudio.com/listener for privacy information.

GoodRx is a marketplace, sort of like the Switzerland of health care, working with all constituents on behalf of the customer, co-founder and co-CEO Doug Hirsch explains to Bloomberg Intelligence. In this episode of the Tech Disruptors podcast, Hirsch sits down with BI analyst Jonathan Palmer to talk about GoodRx's evolving business model, the power of its brand and why he's not worried about structural changes to the market for prescription drugs.

 GoodRx is a marketplace, sort of like the Switzerland of health care, working with all constituents on behalf of the customer, co-founder and co-CEO Doug Hirsch explains to Bloomberg Intelligence. In this episode of the Vanguards of Health Care podcast, Hirsch sits down with BI analyst Jonathan Palmer to talk about GoodRx's evolving business model, the power of its brand and why he's not worried about structural changes to the market for prescription drugs. See omnystudio.com/listener for privacy information.

He didn't come from a racing family. He followed in the footsteps of his father and qualified as a doctor. How Jonathan Palmer ended up driving in Formula 1 is an intriguing tale of passion for racing, intuition and plenty of graft. Palmer initially competed in Formula Ford but after qualifying as a doctor, he decided to focus on racing professionally. He became British Formula 3 champion in 1981 and European Formula 3 champion in 1983. That year, Williams gave him his F1 debut at the European Grand Prix. He would go on to race for RAM, Zakspeed and Tyrrell over the next six years – scoring 14 championship points along the way. Palmer takes Tom Clarkson through his unique journey from studying medicine to competing in Formula 1. He reflects on some memorable drives in Monaco and we hear wonderful insight into what it was like working with Ayrton Senna as a test driver for McLaren in 1990. Palmer, whose son Jolyon also raced in F1 for Renault in 2016 and 2017, became part of the BBC's Formula 1 coverage after retiring. He recalls working the day Senna lost his life at Imola in May 1994. Follow, rate and review F1 Beyond The Grid and share this episode using #F1BeyondTheGrid.

Trancarent's at-risk care model enables consumers to reach a physician in less than 60 second with solutions spanning everyday care to pharmacy, home and specialty, CEO and Founder Glen Tullman explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, BI analyst Jonathan Palmer talks with Tullman and explores the health care challenges facing self-insured employers, the shifting landscape of primary care and the benefits of Transcarent's acquisition of 98point6's virtual care platform. See omnystudio.com/listener for privacy information.

Definitive Healthcare provides commercial intelligence solutions and its software-as-a-service platform is a key differentiator in the $10 billion marketplace that's helping to drive profitable growth, CEO Robert Musslewhite explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, BI analyst Jonathan Palmer sits down with Musslewhite for an in-depth interview about the company and how it's data transformation and analytics are helping its clients to uncover opportunities.See omnystudio.com/listener for privacy information.

Omada Health's virtual-first care (V1C) platform and other digital solutions are building momentum across employers and providers, with one in 10 commercially insured adults having access to its products and services, CEO and co-founder Sean Duffy explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, BI analyst Jonathan Palmer talks about the genesis of the company with Duffy and explores the challenges facing benefits managers, the evolution of virtual care and the rapid changes coming to primary care via M&A.See omnystudio.com/listener for privacy information.

Zocdoc Founder & CEO Oliver Kharraz joins Bloomberg Intelligence healthcare analyst Jonathan Palmer to discuss how Zocdoc's evolving business model is creating sustainable value across the healthcare system. We also dive into some of the latest trends at the intersection of technology and healthcare.See omnystudio.com/listener for privacy information.

The Spatial Monitoring and Reporting Tool (SMART) was created by a coalition of conservation organizations to take historical data and create geospatial mapping tools that enable more efficient deployment of park rangers to prevent poaching. SMART had demonstrated significant improvements in patrol coverage, with some observed reductions in poaching. Then a new analytic tool, the Protection Assistant for Wildlife Security (PAWS), was created to use artificial intelligence (AI) and machine learning (ML) to try to predict where poachers would be likely to strike. Jonathan Palmer, Executive Director of Conservation Technology for the Wildlife Conservation Society, already had a good data analytics tool to help park rangers manage their patrols. Would adding an AI- and ML-based tool improve outcomes or introduce new problems?

Zocdoc Founder & CEO Oliver Kharraz joins Bloomberg Intelligence healthcare analyst Jonathan Palmer to discuss how Zocdoc's evolving business model is creating sustainable value across the healthcare system. We also dive into some of the latest trends at the intersection of technology and healthcare.

Neil Grossman, former CIO with TKNG Capital, joins the show to talk about the Fed and breaks down Jay Powell's comments from yesterday. Michael Cuggino, President & Portfolio Manager of the Permanent Portfolio Family of Funds, joins the program to discuss sectors he likes and gives his market outlook. Danielle DiMartino Booth, CEO and Chief Strategist of Quill Intelligence, joins the program to discuss Jay Powell's comments from Tuesday and the Fed's rate hike path. Jonathan Palmer, Senior Industry Analyst with Bloomberg Intelligence, joins the program to break down CVS earnings and discuss their acquisition of Oak Street Health. Bryan Whalen, co-chief investment officer and generalist portfolio manager with TCW Investment Management, joins us for a monthly TCW segment for the latest on fixed income markets. Hosted by Kriti Gupta and John Tucker.See omnystudio.com/listener for privacy information.

Callie Cox, US Investment Analyst at eToro, joins us in studio to discuss stocks she likes and outlook for equities in 2023. Wendy Thomas, President and CEO at Secureworks (NASDAQ: SCWX), joins the program to talk about the state of cybersecurity to start the year and concerns for corporations and governments based on what clients are telling her. Anurag Rana, Senior Tech analyst with Bloomberg Intelligence, joins to discuss Microsoft's potential investment in OpenAI. George Bory, chief investment strategist, fixed income with Allspring Global Investments, joins the program to discuss fixed income investments in 2023 and what the bond market is telling us about a potential recession in 2023. Jonathan Palmer, Senior Equity Research Analyst with Bloomberg Intelligence, joins to discuss CVS Health exploring a multi-billion dollar deal with Oak Street. Hosted by Paul Sweeney and Matt Miller.See omnystudio.com/listener for privacy information.

Lee Klaskow, Senior Logistics Analyst with Bloomberg News, joins the show to talk about the latest on the supply chain and shipping in the US. Natalie Trevithick, Head of Investment Grade Credit Strategy at Payden & Rygel, joins us to talk about stocks and sectors she likes amid economic uncertainty. Anurag Rana, Senior Software and IT Analyst with Bloomberg Intelligence, joins us to discuss his latest tech research and Big Tech earnings. Jonathan Palmer, Senior Equity Research Analyst with Bloomberg Intelligence, joins the show to discuss CVS earnings and outlook for the company as well as healthcare companies CVS, Walgreens, and WalMart agreeing to a $12 billion opioid pact. Randy Schwimmer, co-head of lending at Churchill Asset Management, joins the show to talk about his views on inflation ahead of the FOMC meeting, the risk of deflation, and private credit. Hosted by Paul Sweeney and Kriti Gupta. See omnystudio.com/listener for privacy information.

Vince Cignarella, Bloomberg News macro strategist, and Jennifer Lee, Senior Economist and Managing Director at BMO Capital Markets, join the show to discuss the latest CPI and PPI data. Mona Mahajan, Senior Investment Strategist with Edward Jones, discusses her sector picks and outlook for the equity market in 2022. Anna Wong, Chief US Economist with Bloomberg Economics and Bloomberg News Markets correspondent Kriti Gupta join the show to break down the latest inflation reading. Jonathan Palmer, Senior Equity Research Analyst with Bloomberg Intelligence, joins the show to discuss Walgreens earnings and outlook for the company. Jeffrey Cleveland, director and Chief Economist with Payden & Rygel, joins the show to discuss the latest inflation data, previews bank earnings, and discusses what to expect from the economy in Q4. Hosted by Paul Sweeney and Matt Miller.See omnystudio.com/listener for privacy information.

Listen to a 15-minute clip from our 1hr Last Blast podcast with former F1 driver, Dr Jonathan Palmer. To listen to the full interview, head to The Intercooler app or the-intercooler.com and check out the Video & Podcast page. Last Blast is proudly sponsored by car insurance specialist, Footman James. Visit footmanjames.co.uk to find out more. 

Priya Misra, managing director and Global Head of Rates Strategy at TD Securities, joins the show to talk about the Fed, interest rates, and outlook for the economy in 2022. Matt Winkler, editor-in-chief emeritus at Bloomberg News, joins the show to discuss his recent column about Ron DeSantis and ESG investing. Tim Craighead, Director of Research and Senior European Strategist at Bloomberg Intelligence, joins the show to discuss Liz Truss and Europe's energy crisis and how it's all impacting markets. Jonathan Palmer, Senior Equity Research Analyst & Team Leader, Healthcare, joins the show to discuss CVS Health's acquisition of Signify Health. Sean Joyce, PwC's global cybersecurity and privacy leader and former Deputy Director with the FBI, joins the show to discuss cybersecurity concerns from the c-suite. Hosted by Paul Sweeney and Matt Miller.See omnystudio.com/listener for privacy information.

Whether it's drones recording video in previously inaccessible areas, artificial intelligence sorting through thousands of camera trap images, or microphones in the ocean recording whale sounds to determine which species are present, technology is transforming the practice of conservation today. To find out how WCS is using technology to up its conservation game, Nat Moss checked in with Jonathan Palmer and Danielle LaBruna from WCS's Conservation Technology team.